Hemostemix closes $1M private placement, restates Q3 financials

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) announced it is closing up to $1,000,000 in a non-brokered private placement, selling units at $0.05 each. Each unit consists of one common share and one half common share purchase warrant, with each whole warrant entitling the holder to purchase one common share at $0.12 for 24 months from closing.

The warrants include an accelerated expiry provision: if the weighted average closing price of the common shares on the TSX Venture Exchange equals or exceeds $0.15 for 10 consecutive trading days after four months and one day from closing, the company may accelerate the warrant expiry to 30 days following a press release notice.

Proceeds are designated for sales, marketing, patient acquisition, physician education, commercialization initiatives, production and manufacturing expenses for ACP-01 treatments, regulatory and filing fees related to submissions to the Ministry of Health and Wellness of the Bahamas, and general working capital. All securities are subject to a four-month hold period under Canadian securities laws.

Certain directors may participate in the placement, constituting a related party transaction under Multilateral Instrument 61-101. The company is relying on exemptions from formal valuation and minority shareholder approval requirements.

Separately, Hemostemix filed restated unaudited condensed interim financial statements and MD&A for the nine-month period ended September 30, 2025, on SEDAR+. The restatement corrects a material misstatement in the accounting treatment of Therapeutic Convertible Debentures issued July 14, 2025, which should have been recorded as a single liability under Fair Value Through Profit or Loss per IFRS 9.

Key restated figures include a debenture liability increase from $3.4 million to $3.5 million, professional fees rising from $731,000 to $753,000, and foreign exchange expense increasing from $110,000 to $158,000. The company stated the restatement does not affect its cash position or operating activities. The previously filed Q3 statements from November 28, 2025 should no longer be relied upon.

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• Bessent on bonds: buyback could be more than 4 billion - CNBC
• Invesco cuts fees 20% amid redemption backlog in real estate fund - Bloomberg